KR20190071990A - Fermented ginseng and composition for improving cognitive function using a combination fermentation strain - Google Patents
Fermented ginseng and composition for improving cognitive function using a combination fermentation strain Download PDFInfo
- Publication number
- KR20190071990A KR20190071990A KR1020170172982A KR20170172982A KR20190071990A KR 20190071990 A KR20190071990 A KR 20190071990A KR 1020170172982 A KR1020170172982 A KR 1020170172982A KR 20170172982 A KR20170172982 A KR 20170172982A KR 20190071990 A KR20190071990 A KR 20190071990A
- Authority
- KR
- South Korea
- Prior art keywords
- cognitive function
- ginseng
- improving
- strain
- composition
- Prior art date
Links
- 230000003920 cognitive function Effects 0.000 title claims abstract description 122
- 235000008434 ginseng Nutrition 0.000 title claims abstract description 107
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 title claims abstract description 97
- 235000003140 Panax quinquefolius Nutrition 0.000 title claims abstract description 97
- 239000000203 mixture Substances 0.000 title claims abstract description 86
- 238000000855 fermentation Methods 0.000 title claims abstract description 53
- 230000004151 fermentation Effects 0.000 title claims abstract description 53
- 241000208340 Araliaceae Species 0.000 title abstract description 4
- 229930182490 saponin Natural products 0.000 claims abstract description 13
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims abstract description 12
- 101100173618 Gibberella zeae (strain ATCC MYA-4620 / CBS 123657 / FGSC 9075 / NRRL 31084 / PH-1) FGM4 gene Proteins 0.000 claims abstract description 11
- 101100173615 Gibberella zeae (strain ATCC MYA-4620 / CBS 123657 / FGSC 9075 / NRRL 31084 / PH-1) FGM1 gene Proteins 0.000 claims abstract description 10
- 230000036983 biotransformation Effects 0.000 claims abstract description 3
- 240000004371 Panax ginseng Species 0.000 claims description 105
- 239000003814 drug Substances 0.000 claims description 45
- 239000000284 extract Substances 0.000 claims description 43
- 229940079593 drug Drugs 0.000 claims description 35
- 235000002789 Panax ginseng Nutrition 0.000 claims description 28
- 241000186660 Lactobacillus Species 0.000 claims description 23
- 229940039696 lactobacillus Drugs 0.000 claims description 23
- 235000012907 honey Nutrition 0.000 claims description 22
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 18
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 14
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 14
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 14
- 235000013399 edible fruits Nutrition 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- 241000186016 Bifidobacterium bifidum Species 0.000 claims description 10
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims description 10
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 9
- 229930003268 Vitamin C Natural products 0.000 claims description 9
- 238000012258 culturing Methods 0.000 claims description 9
- 235000019154 vitamin C Nutrition 0.000 claims description 9
- 239000011718 vitamin C Substances 0.000 claims description 9
- 235000011201 Ginkgo Nutrition 0.000 claims description 8
- 244000194101 Ginkgo biloba Species 0.000 claims description 8
- 235000008100 Ginkgo biloba Nutrition 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 244000199866 Lactobacillus casei Species 0.000 claims description 7
- 235000013958 Lactobacillus casei Nutrition 0.000 claims description 7
- 229940017800 lactobacillus casei Drugs 0.000 claims description 7
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims description 6
- 229930003270 Vitamin B Natural products 0.000 claims description 6
- YEFOAORQXAOVJQ-RZFZLAGVSA-N schisandrol a Chemical compound C1[C@H](C)[C@@](C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-RZFZLAGVSA-N 0.000 claims description 6
- 235000019156 vitamin B Nutrition 0.000 claims description 6
- 239000011720 vitamin B Substances 0.000 claims description 6
- 240000002769 Morchella esculenta Species 0.000 claims description 5
- 235000002779 Morchella esculenta Nutrition 0.000 claims description 5
- 244000299790 Rheum rhabarbarum Species 0.000 claims description 4
- 235000009411 Rheum rhabarbarum Nutrition 0.000 claims description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 4
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 4
- 241000332371 Abutilon x hybridum Species 0.000 claims description 3
- 241000282806 Rhinoceros Species 0.000 claims description 3
- 235000010149 Brassica rapa subsp chinensis Nutrition 0.000 claims 2
- 235000000536 Brassica rapa subsp pekinensis Nutrition 0.000 claims 2
- 241000499436 Brassica rapa subsp. pekinensis Species 0.000 claims 2
- 235000006533 astragalus Nutrition 0.000 claims 1
- 229930182470 glycoside Natural products 0.000 abstract description 7
- -1 saponin glycoside Chemical class 0.000 abstract description 3
- 235000005911 diet Nutrition 0.000 abstract description 2
- 230000000378 dietary effect Effects 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 20
- 229930182494 ginsenoside Natural products 0.000 description 18
- 239000000843 powder Substances 0.000 description 18
- 230000000052 comparative effect Effects 0.000 description 14
- 239000000243 solution Substances 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 229940089161 ginsenoside Drugs 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 235000017709 saponins Nutrition 0.000 description 11
- 229930003231 vitamin Natural products 0.000 description 11
- 235000013343 vitamin Nutrition 0.000 description 11
- 239000011782 vitamin Substances 0.000 description 11
- 229940088594 vitamin Drugs 0.000 description 11
- 239000012141 concentrate Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 235000015203 fruit juice Nutrition 0.000 description 9
- 150000007949 saponins Chemical class 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- 230000006872 improvement Effects 0.000 description 8
- RWXIFXNRCLMQCD-JBVRGBGGSA-N (20S)-ginsenoside Rg3 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RWXIFXNRCLMQCD-JBVRGBGGSA-N 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 235000019634 flavors Nutrition 0.000 description 7
- 150000002338 glycosides Chemical group 0.000 description 7
- 235000005979 Citrus limon Nutrition 0.000 description 6
- 244000131522 Citrus pyriformis Species 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000003078 antioxidant effect Effects 0.000 description 5
- 239000006227 byproduct Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 240000004307 Citrus medica Species 0.000 description 4
- 235000002791 Panax Nutrition 0.000 description 4
- 241000208343 Panax Species 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 235000019640 taste Nutrition 0.000 description 4
- 150000003722 vitamin derivatives Chemical class 0.000 description 4
- 241001672694 Citrus reticulata Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000003930 cognitive ability Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000010298 pulverizing process Methods 0.000 description 3
- 230000001953 sensory effect Effects 0.000 description 3
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 2
- 235000017491 Bambusa tulda Nutrition 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- AGBCLJAHARWNLA-DQUQINEDSA-N Ginsenoside RG2 Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@@](C)(O)CCC=C(C)C)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O AGBCLJAHARWNLA-DQUQINEDSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- 244000082204 Phyllostachys viridis Species 0.000 description 2
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 description 2
- 229930003779 Vitamin B12 Natural products 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 2
- 239000011425 bamboo Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 235000020971 citrus fruits Nutrition 0.000 description 2
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 2
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 2
- 230000019771 cognition Effects 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 238000000132 electrospray ionisation Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 229940102465 ginger root Drugs 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 229940025878 hesperidin Drugs 0.000 description 2
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 2
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229940087305 limonene Drugs 0.000 description 2
- 235000001510 limonene Nutrition 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 235000019163 vitamin B12 Nutrition 0.000 description 2
- 239000011715 vitamin B12 Substances 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 239000001841 zingiber officinale Substances 0.000 description 2
- AGBCLJAHARWNLA-UHFFFAOYSA-N (20R)-ginsenoside Rg2 Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C3C(C)(C)C(O)CCC3(C)C3C(C4(CCC(C4C(O)C3)C(C)(O)CCC=C(C)C)C)(C)C2)OC(CO)C(O)C1O AGBCLJAHARWNLA-UHFFFAOYSA-N 0.000 description 1
- CKUVNOCSBYYHIS-UHFFFAOYSA-N (20R)-ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CCC3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1O CKUVNOCSBYYHIS-UHFFFAOYSA-N 0.000 description 1
- RAQNTCRNSXYLAH-RFCGZQMISA-N (20S)-ginsenoside Rh1 Chemical compound O([C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@H]2C[C@@H](O)[C@H]3[C@@]([C@@]2(C1)C)(C)CC[C@@H]3[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RAQNTCRNSXYLAH-RFCGZQMISA-N 0.000 description 1
- CKUVNOCSBYYHIS-IRFFNABBSA-N (20S)-ginsenoside Rh2 Chemical compound O([C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CKUVNOCSBYYHIS-IRFFNABBSA-N 0.000 description 1
- CKUVNOCSBYYHIS-LGYUXIIVSA-N 20(R)-Ginsenoside Rh2 Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1C(C)(C)[C@H]2[C@@](C)([C@H]3[C@](C)([C@@]4(C)[C@H]([C@H](O)C3)[C@@H]([C@](O)(CC/C=C(\C)/C)C)CC4)CC2)CC1 CKUVNOCSBYYHIS-LGYUXIIVSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 240000001810 Angelica gigas Species 0.000 description 1
- 235000018865 Angelica gigas Nutrition 0.000 description 1
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 241000951471 Citrus junos Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 235000011511 Diospyros Nutrition 0.000 description 1
- 244000236655 Diospyros kaki Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 206010017807 Gastric mucosal hypertrophy Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- IBFYXTRXDNAPMM-BVTMAQQCSA-N Geniposide Chemical compound O([C@@H]1OC=C([C@@H]2[C@H]1C(=CC2)CO)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O IBFYXTRXDNAPMM-BVTMAQQCSA-N 0.000 description 1
- IBFYXTRXDNAPMM-FZEIBHLUSA-N Geniposide Natural products COC(=O)C1=CO[C@@H](O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O)[C@H]2[C@@H]1CC=C2CO IBFYXTRXDNAPMM-FZEIBHLUSA-N 0.000 description 1
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 description 1
- XIRZPICFRDZXPF-UHFFFAOYSA-N Ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CC(O)C3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O XIRZPICFRDZXPF-UHFFFAOYSA-N 0.000 description 1
- RAQNTCRNSXYLAH-UHFFFAOYSA-N Ginsenoside Rh1 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(C3)C)(C)C1C(O)CC2C1(C)CCC(O)C(C)(C)C1C3OC1OC(CO)C(O)C(O)C1O RAQNTCRNSXYLAH-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 1
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- 235000003143 Panax notoginseng Nutrition 0.000 description 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 description 1
- 241001674048 Phthiraptera Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- KYWSCMDFVARMPN-LCSVLAELSA-N Saikosaponin D Chemical compound O([C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@]([C@H]3[C@]([C@@H]4[C@@]([C@@]5(C[C@@H](O)[C@]67CO[C@]5([C@@H]6CC(C)(C)CC7)C=C4)C)(C)CC3)(C)CC2)(C)CO)O[C@@H]([C@@H]1O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O KYWSCMDFVARMPN-LCSVLAELSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000003113 alkalizing effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- VGLLGNISLBPZNL-RBUKDIBWSA-N arborescoside Natural products O=C(OC)C=1[C@@H]2C([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)=C(CO)CC2 VGLLGNISLBPZNL-RBUKDIBWSA-N 0.000 description 1
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 1
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 1
- 229960003321 baicalin Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003653 coastal water Substances 0.000 description 1
- 230000037411 cognitive enhancing Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- FVIZARNDLVOMSU-IRFFNABBSA-N ginsenoside C-K Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FVIZARNDLVOMSU-IRFFNABBSA-N 0.000 description 1
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 description 1
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 description 1
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 description 1
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000003646 hair health Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000015784 hyperosmotic salinity response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 235000021109 kimchi Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007087 memory ability Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- JURZHOVRCOWZFN-UHFFFAOYSA-N notoginsenoside R1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5C(CC34C)OC6OC(COC7OCC(O)C(O)C7O)C(O)C(O)C6O)C JURZHOVRCOWZFN-UHFFFAOYSA-N 0.000 description 1
- 235000019645 odor Nutrition 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 229930192014 saikosaponin Natural products 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 229940124513 senna glycoside Drugs 0.000 description 1
- 229930186851 sennoside Natural products 0.000 description 1
- IPQVTOJGNYVQEO-KGFNBKMBSA-N sennoside A Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC2=C1C(=O)C1=C(O)C=C(C(O)=O)C=C1[C@@H]2[C@H]1C2=CC(C(O)=O)=CC(O)=C2C(=O)C2=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C=CC=C21 IPQVTOJGNYVQEO-KGFNBKMBSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019614 sour taste Nutrition 0.000 description 1
- 235000003687 soy isoflavones Nutrition 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/10—Products from fruits or vegetables; Preparation or treatment thereof of tuberous or like starch containing root crops
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2124—Ginseng
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
본 발명은 조합발효균주를 이용한 발효인삼 및 인지기능개선용 조성물에 관한 것으로, 더욱 구체적으로 조합발효균주로 인삼을 발효시켜 인지기능에 관련되는 진세노사이드가 풍부한 FGM1 또는 FGM4 형태의 발효물을 얻고, 인기지능개선 약재군의 발효 추출물을 혼합하여 인지기능개선 효과가 더욱 향상된 조합발효균주를 이용한 발효인삼 및 인지기능개선용 조성물에 관한 것이다.The present invention relates to a fermented ginseng and a composition for improving cognitive function using a combination fermentation strain, and more particularly, to a fermented product of FGM1 or FGM4 form rich in ginsenosides related to cognitive function by fermenting ginseng, The present invention relates to a fermented ginseng and a composition for improving cognitive function using a combination fermentation strain having improved cognitive function improving effect by mixing fermented extracts of popular intelligence improving medicinal group.
인삼은 전통적으로 파낙스속의 다년생 식물이며, 분류학상 오가과(Araliaceae)에 속하는 다년생 숙근초이다. 대표적으로 고려삼(Panax ginseng), 서양삼(Panax quinquefolia), 전칠삼(삼칠, Panax notoginseng), 히말라야삼(Panax pseudoginseng), 베트남삼(Panax vietnamesis) 등이 있다. Ginseng is traditionally a perennial plant of the genus Panax, and is a perennial herbaceous perennial belonging to the genus Araliaceae. Panax ginseng, Panax quinquefolia, Panax notoginseng, Panax pseudoginseng and Panax vietnamesis are the representative examples.
이들 중 고려인삼은 기타삼에 비하여 더 효과적으로 기를 강하게 하고 다양한 효능(노화억제, 스트레스와 허약회복, 혈행조절기능)을 주는 것으로 오래전부터 알려져 왔다. Among them, Korean ginseng has been known for a long time to strengthen the flame more effectively and to give various effects (inhibition of aging, restoration of weakness and restoration of blood circulation, and regulation of blood circulation).
이러한 고려인삼의 유효성분인 사포닌은 아글리콘(aglycone) 구조의 차이에 따라 디올(diol)과 트리올(triol)계로 구별되며, 아글리콘 C3, C6, C20 탄소위치에 연결된 배당체 사슬이 장내 세균(효소)의 작용으로 분해(효소작용전환)되어야 비로소 체내 흡수된다.Saponin, an active ingredient of Korean ginseng, is classified into diol and triol according to the difference in aglycone structure, and the glycoside chain linked to carbon positions of aglycons C3, C6 and C20 is different from that of intestinal bacteria Enzymes), it is only absorbed into the body.
한편, 장내 세균의 구성은 체질, 식습관, 항생 물질의 복용 및 스트레스 등의 영향을 받기 쉬워서 배당체를 가수분해하는 능력은 현저한 개인차를 보인다.On the other hand, the composition of intestinal bacteria is susceptible to the constitution, dietary habit, antibiotic use and stress, and thus the ability to hydrolyze the glycosides exhibits remarkable individual differences.
따라서 배당체의 흡수에서도 현저한 차이가 발생하게 되고 이것이 약효에 있어서 개인차가 나타나는 한 원인으로 알려져 있다(Hasegawa H. et al., Planta Medica, 63, pp436-440, 1997).Thus, there is a significant difference in the absorption of glycosides, which is known to cause individual differences in drug efficacy (Hasegawa H. et al., Planta Medica, 63, pp436-440, 1997).
이는 마우스를 이용한 암전이 실험으로도 뒷받침되는데, 장내 세균의 배당체 가수분해 능력에 따라 각각의 마우스에서 항전이 효과가 다르게 나타나는 결과에서, 인삼사포닌의 배당체에 대한 가수분해 능력이 약효에 큰 영향을 미치는 요인임을 알 수 있다(Hasegawa H. et al., Planta Medica,64, pp696-700, 1998).This is due to the fact that the effect of hydrolysis of ginseng saponin on the glycosylation of ginseng saponins has a great effect on the drug efficacy. (Hasegawa H. et al., Planta Medica, 64, pp696-700, 1998).
한편, 배당체 분해물 FGM1은 종양세포의 세포 분열을 제어해 세포의 세포자살(apoptosis)을 유도하여 종양의 증식 및 전이를 억제하는 작용4이 있으며, FGM4는 수상(樹狀) 세포로부터 인터페론 (interferon gamma)의 (産生)을 항진하여 면역 발란스를 Th1로 유도하는 것에 의해 항종양면역을 높이는 작용이 있다.(Takei, M. et al., Biochem. Pharmacol., 68, pp441-452, 2004)On the other hand, the glycosylase degradation product FGM1 regulates cell division of tumor cells to induce cell apoptosis, thereby inhibiting the proliferation and metastasis of the tumor. FGM4 is an interferon gamma (Takei, M. et al., Biochem. Pharmacol., 68, pp441-452, 2004). In addition, the anti-tumor immunity is enhanced by inducing the immune balance to Th1.
이와 같이 사포닌의 배당체 분해능을 가진 미생물 종류와 분해조건에 따라 새로운 분자구조와 패턴을 가진 배당체 분해물(새로운 진세노사이드)들이 제조되면서 이들 새로운 구조의 진세사이드들에 의하여 인체 생리현상에 미치는 효능이 다양화 되고 있다.As such, saponin degraded glycosides with new molecular structures and patterns (new ginsenosides) were produced according to microbial species having decomposing ability of glycosides and decomposition conditions, and the effects of these new structures on the physiological phenomena were various .
발효 진행과정에서 선택된 균주에 따라 불쾌한 냄새의 부산물이 생성되므로 발효생성물 그 자체를 사용하는데 문제가 있었으나 락토바실러스 하세가와 균주는 이러한 문제를 해결하였다.Lactobacillus Hasegawa strain solved this problem, though it was problematic to use the fermentation product itself because by-product of unpleasant smell was generated depending on the strain selected during the fermentation process.
한편, 의식주의 개선현상으로 사람의 평균수명이 계속 늘어나는 추세이며, 노령인구의 증가에 따라 육체의 질병과 함께 우울증, 건망증, 치매와 알츠하이머를 포함하는 통칭 인지기능의 장애 현상이 사회문제로 급격이 대두되고 있다.On the other hand, the average life expectancy of a person is continuously increasing due to the improvement of the food and shelter, and as the aging population increases, the disorder of the cognitive function including the depression, amnesia, dementia and Alzheimer Is emerging.
알츠하이머, 치매, 등 인지기능 치료제가 합성신약으로 다양하게 개발되고 있으나 메스꺼움, 식욕감퇴, 구토, 설사 등의 부작용을 일으키는 것으로 알려지면서 합성신약의 사용은 아직 매우 제한적이다.Alzheimer's, dementia and other cognitive function drugs are being developed as synthetic drugs, but the use of synthetic drugs is still limited as it is known to cause side effects such as nausea, loss of appetite, vomiting and diarrhea.
따라서, 장기복용에도 부작용이 적은 천연약재를 이용한 인지기능개선용 건강기능식품의 개발과 상품화가 요구되고 있으며, 이에 대한 진전된 결과가 나타나고 있다. Therefore, development and commercialization of a health functional food for improving cognitive function using natural medicines, which have little side effects even for long-term use, are required, and progress has been made on this.
이에 따라, 국내 한방연구에서 인지능력과 기억력 개선을 위한 건강기능식품으로 당귀, 비파엽, 구기자, 은행잎, 등이 다양하게 개발되고 있으나, 아직은 효과가 제한적이고 활용성이 크지 않다. As a result, various functional foods for improving cognitive ability and memory in Korean oriental medicine researches have been developed, such as Angelica gigas Nakai, Non - leaf lice, Gugija, Ginkgo leaf, etc.
따라서, 발효 시 부산물에 의한 부작용이 없고, 배당체 성분을 분해하여 진세노사이드를 수득할 수 있으며, 효능에 대한 생리의학적 해석이 가능하고 효과가 뛰어난 새로운 인지기능개선용 조성물의 개발이 절실하게 요구된다.Therefore, there is a desperate need to develop a novel composition for improving cognition, which has no adverse effects due to byproducts during fermentation, can dissolve glycoside components to obtain ginsenosides, is capable of physiological analysis on efficacy, and has excellent effects .
상기와 같은 문제를 해결하고자, 본 발명은 조합발효균주로 인삼을 발효시켜 인지기능에 관련되는 진세노사이드가 풍부한 FGM1 또는 FGM4 형태의 발효물을 얻고, 인기지능개선 약재군의 발효 추출물을 혼합하여 인지기능개선 효과가 더욱 향상된 조합발효균주를 이용한 발효인삼 및 인지기능개선용 조성물을 제공하는데 있다.In order to solve the above problems, the present invention relates to a fermented product of FGM1 or FGM4 type, rich in ginsenoside, which is related to cognitive function by fermenting ginseng as a combined fermentation broth, And a composition for improving cognitive function using fermented ginseng using a combination fermentation strain having improved function improving effect.
상기와 같은 과제를 해결하기 위해서, 본 발명의 제1 실시예에 따른 조합발효균주를 이용한 발효인삼은 인삼을 사카로미세스 세레비시아(Saccaharomyces cerevisiae S6-1, KACC93225P)와 식이용 발효균주를 조합한 조합발효균주로 사포닌 배당체 부분을 생물전환하여 얻어진 FGM1 또는 FGM4형태의 발효물을 포함하는 발효인삼을 제공할 수 있다.In order to solve the above problems, the fermented ginseng using the combination fermentation strain according to the first embodiment of the present invention is characterized in that ginseng is combined with Saccharomyces cerevisiae S6-1 (KACC93225P) It is possible to provide a fermented ginseng comprising a fermented product of the FGM1 or FGM4 type obtained by biotransformation of a saponin glycoside moiety.
또한, 상기 인삼은 고려인삼, 고려흑삼, 고려홍삼 및 삼양삼 중 하나인 것을 특징으로 한다.In addition, the ginseng is one of Korean ginseng, Korean black ginseng, Korean red ginseng, and Samyang sam.
또한, 상기 식이용 발효균주는 락토바실러스 카제이 하세가와 FERM BP-10123주(Lactobacillus casei strain Hasegawa FERM BP-10123주), 락토바실러스 DSM 2024주(Lactobacillus DSM 2024주), 락토바실러스 플란타룸 ATCC 14947주(Lactobacillus, plantarum ATCC 14947주) 및 비피도박테리움 비피둠 JCM 7002주(Bifidobacterium bifidum JCM 7002주) 중 1종 이상인 것을 특징으로 한다.Lactobacillus casei strain Hasegawa FERM BP-10123 strain, Lactobacillus strain DSM 2024 strain (Lactobacillus strain DSM 2024 strain), Lactobacillus planta ATCC 14947 strain (strain Lactobacillus strains) Lactobacillus, plantarum ATCC 14947) and Bifidobacterium bifidum JCM 7002 (Bifidobacterium bifidum JCM 7002 strain).
또한, 본 발명의 제1 실시예에 따른 인지기능개선용 조성물은 발효인삼을 포함하는 인지기능개선용 조성물을 제공할 수 있다.In addition, the composition for improving the cognitive function according to the first embodiment of the present invention can provide a composition for improving the cognitive function including fermented ginseng.
또한, 상기 인지기능개선용 조성물은 인지기능개선 약재군 추출물을 더 포함할 수 있다.In addition, the composition for improving cognitive function may further comprise a cognitive function improving drug group extract.
또한, 상기 인지기능개선 약재군은 원지, 복령, 참당귀, 은행잎, 오미자, 창포, 지황, 천마, 도라지, 모렐버섯 및 황기 중 하나 이상인 것을 특징으로 한다.In addition, the cognitive function improving medicament group is characterized in that it is at least one selected from the group consisting of a raw material, a bamboo shoot, a ginger root, a ginkgo leaf, an omija, an iris, a rhubarb, a rhinoceros, a bellflower, a morel mushroom and a vulgaris.
또한, 상기 인지기능개선용 조성물은 과실액 및 벌꿀 중 하나 이상을 더 포함하는 것을 특징으로 한다.Further, the composition for improving cognitive function is characterized by further comprising at least one of fruit solution and honey.
또한, 상기 인지기능개선용 조성물은 비타민C 및 활성비타민 B군을 더 포함하는 것을 특징으로 한다.The composition for improving cognitive function further comprises vitamin C and an active vitamin B group.
또한, 상기 인지기능개선용 조성물은 모랑가잎 추출물을 더 포함하는 것을 특징으로 한다.In addition, the composition for improving the cognitive function is characterized by further comprising a Moranganga leaf extract.
또한, 상기 인지기능개선용 조성물은 분말, 과립, 환, 음료, 캡슐 및 농축액 중 하나의 형태인 것을 특징으로 한다.The composition for improving cognitive function is characterized by being in the form of a powder, a granule, a ring, a beverage, a capsule and a concentrate.
또한, 본 발명의 제2 실시예에 따른 인지기능개선용 조성물은 인삼 및 인지기능개선 약재군을 혼합하고 사카로미세스 세레비시아(Saccaharomyces cerevisiae S6-1, KACC93225P)와 식이용 발효균주를 조합한 조합발효균주를 접종하고 배양하여 얻어진 인지기능개선용 조성물을 제공할 수 있다.In addition, the composition for improving the cognitive function according to the second embodiment of the present invention is prepared by mixing ginseng and a cognitive function improving drug group, combining Saccaharomyces cerevisiae S6-1 (KACC93225P) with a food-use fermentation strain A composition for cognitive function improvement obtained by inoculating and culturing a combination fermentation strain can be provided.
또한, 상기 인지기능개선 약재군은 원지, 복령, 참당귀, 은행잎, 오미자, 창포, 지황, 천마, 도라지, 모렐버섯 및 황기 중 하나 이상인 것을 특징으로 한다.In addition, the cognitive function improving medicament group is characterized in that it is at least one selected from the group consisting of a raw material, a bamboo shoot, a ginger root, a ginkgo leaf, an omija, an iris, a rhubarb, a rhinoceros, a bellflower, a morel mushroom and a vulgaris.
또한, 상기 인지기능개선용 조성물은 배양 후 과실액 및 벌꿀 중 하나 이상을 더 포함하는 것을 특징으로 한다.The composition for improving cognitive function may further comprise at least one of a fruit solution and honey after culturing.
또한, 상기 인지기능개선용 조성물은 배양 후 비타민C 및 활성비타민 B군을 더 포함하는 것을 특징으로 한다.The composition for improving cognitive function further comprises vitamin C and an active vitamin B group after culturing.
또한, 상기 인지기능개선용 조성물은 배양 후 모랑가잎 추출물을 더 포함하는 것을 특징으로 한다.In addition, the composition for improving the cognitive function further comprises a Morangia leaf extract after culturing.
본 발명의 실시예에 따른 조합발효균주를 이용한 발효인삼 및 인지기능개선용 조성물은 조합발효균주로 인삼을 발효시켜 FGM1 또는 FGM4 형태의 발효물을 얻어 인지기능에 관련된 진세노사이드가 풍부하여 인지기능개선 효과가 크다.The composition for fermented ginseng and cognitive function improvement using the combination fermentation strain according to an embodiment of the present invention is characterized in that the combination fermented ginseng fermented mainly ginseng to obtain FGM1 or FGM4 type fermented product, The effect is great.
또한, 인기지능개선 약재군 추출물 혹은 인지기능개선 약재군을 혼합하여 인지기능개선 효과가 더욱 향상될 수 있다.In addition, the cognitive function improving effect can be further improved by mixing the popular intelligent improving medicinal group extract or the cognitive function improving medicinal group.
또한, 조합발효균주로 인삼 및 인지기능개선 약재군을 발효시켜 발효시 불쾌한 부산물이 생성되지 않으므로, 발효 후 별도의 정제없이 균 및 배지를 포함한 형태 그대로 섭취가능하며, 풍미, 물성 및 작업성이 뛰어나다.In addition, since uncomplicated by-products are not produced during the fermentation by fermenting the ginseng and the cognitive function improving medicinal group, the fermented soybean ginseng can be ingested as it is in the form including the germ and the medium without further purification after the fermentation, and is excellent in flavor, physical properties and workability.
도 1은 본 발명의 실시예에 따른 실시예 2의 발효인삼(고려흑삼)의 HPLC-MS/MS 분석 그래프.
도 2는 실시예 2(B) 및 표준품 혼합물(S), 홍삼추출물 A지역(1), 홍삼추출물 B지역(2), 홍삼추출물 C지역(3), 건삼(4), 백삼(5)의 TLC 분석 결과를 나타낸 사진.
도 3은 본 발명의 실시예에 따른 실시예 2(B)의 진세노사이드 함량에 대한 크로마토그램.1 is an HPLC-MS / MS analysis graph of fermented ginseng (Korean black ginseng) of Example 2 according to an embodiment of the present invention.
FIG. 2 is a graph showing the results of the comparison between Example 2 (B) and the standard product mixture (S), red ginseng
Figure 3 is a chromatogram for the ginsenoside content of Example 2 (B) according to an embodiment of the present invention.
이하, 도면을 참조한 본 발명의 설명은 특정한 실시 형태에 대해 한정되지 않으며, 다양한 변환을 가할 수 있고 여러 가지 실시예를 가질 수 있다. 또한, 이하에서 설명하는 내용은 본 발명의 사상 및 기술 범위에 포함되는 모든 변환, 균등물 내지 대체물을 포함하는 것으로 이해되어야 한다.Hereinafter, the description of the present invention with reference to the drawings is not limited to a specific embodiment, and various transformations can be applied and various embodiments can be made. It is to be understood that the following description covers all changes, equivalents, and alternatives falling within the spirit and scope of the present invention.
이하의 설명에서 제1, 제2 등의 용어는 다양한 구성요소들을 설명하는데 사용되는 용어로서, 그 자체에 의미가 한정되지 아니하며, 하나의 구성요소를 다른 구성요소로부터 구별하는 목적으로만 사용된다.In the following description, the terms first, second, and the like are used to describe various components and are not limited to their own meaning, and are used only for the purpose of distinguishing one component from another component.
본 명세서 전체에 걸쳐 사용되는 동일한 참조번호는 동일한 구성요소를 나타낸다.Like reference numerals used throughout the specification denote like elements.
본 발명에서 사용되는 단수의 표현은 문맥상 명백하게 다르게 뜻하지 않는 한, 복수의 표현을 포함한다. 또한, 이하에서 기재되는 "포함하다", "구비하다" 또는 "가지다" 등의 용어는 명세서상에 기재된 특징, 숫자, 단계, 동작, 구성요소, 부품 또는 이들을 조합한 것이 존재함을 지정하려는 것으로 해석되어야 하며, 하나 또는 그 이상의 다른 특징들이나, 숫자, 단계, 동작, 구성요소, 부품 또는 이들을 조합한 것들의 존재 또는 부가 가능성을 미리 배제하지 않는 것으로 이해되어야 한다.As used herein, the singular forms "a", "an" and "the" include plural referents unless the context clearly dictates otherwise. It is also to be understood that the terms " comprising, "" comprising, "or" having ", and the like are intended to designate the presence of stated features, integers, And should not be construed to preclude the presence or addition of one or more other features, integers, steps, operations, elements, components, or combinations thereof.
이하, 본 발명의 실시 예를 첨부한 도 1 내지 도 3을 참조하여 상세히 설명하기로 한다.Hereinafter, embodiments of the present invention will be described in detail with reference to FIGS. 1 to 3 attached hereto.
본 발명의 제1 실시예에 따른 조합발효균주를 이용한 발효인삼은 인삼을 사카로미세스 세레비시아(Saccaharomyces cerevisiae S6-1, KACC93225P)와 식이용 발효균주를 조합한 조합발효균주로 발효시켜 제조될 수 있다.The fermented ginseng using the combination fermentation strain according to the first embodiment of the present invention can be produced by fermenting mainly ginseng with a combination fermenting bacteria in combination with Saccharomyces cerevisiae S6-1 (KACC93225P) have.
이때, 인삼이 배지이고, 인삼 중량 2 내지 7배의 증류수에 인삼을 넣고 살균처리한 후 조합발효균주를 인삼 전체 중량%에 대하여 0.5 내지 30%로 접종하고 25 내지 40℃에서 1 내지 3주 동안 배양될 수 있다.In this case, ginseng is a culture medium, ginseng is put into distilled water of 2 to 7 times the weight of ginseng, sterilized, and the combination fermentation strain is inoculated at 0.5 to 30% with respect to the total weight% of ginseng and incubated at 25 to 40 DEG C for 1 to 3 weeks Lt; / RTI >
즉, 발효인삼은 조합발효균주로 인삼의 사포닌 배당체 부분을 생물전환하여 얻어진 FGM1 또는 FGM4형태의 발효물을 포함하고, 발효 후 정제하지 않은 그대로의 상태이다.That is, the fermented ginseng contains the fermented product of the FGM1 or FGM4 type obtained by bioconversion of the saponin glycoside part of the ginseng, and is not purified after fermentation.
이는 인삼을 조합발효균주로 발효시켜 발효 시에 발생할 수 있는 불쾌한 부산물이 발생하지 않아 정제하지 않고 그대로의 상태로 이용할 수 있는 것이다.This is because ginseng can be fermented mainly in combination with fermenting bacteria, so that unpleasant by-products that may occur during fermentation do not occur and can be used as it is without purification.
이러한 조합발효균주는 사카로미세스 세레비시아(Saccaharomyces cerevisiae S6-1, KACC93225P)와 식이용 발효균주를 조합한 것으로, 사카로미세스 세레비시아(Saccaharomyces cerevisiae S6-1, KACC93225P)는 연안 해역 해수로부터 분리한 신균주로서, 내알콜성, 내염성 및 내냉동성 특성을 나타내며, 또한 사포닌 분자로부터 복합 다당체를 쉽게 분리하는 역할을 한다.Saccaharomyces cerevisiae S6-1 (KACC93225P) is a combination of fermentation broth with fermentation, and Saccaharomyces cerevisiae S6-1 (KACC93225P) is isolated from seawater in coastal waters. As a new strain, it exhibits alcohol resistance, salt tolerance and anti-freezing properties and also plays a role of easily separating complex polysaccharide from saponin molecule.
식이용 발효균주는 락토바실러스 카제이 하세가와 FERM BP-10123주(Lactobacillus casei strain Hasegawa FERM BP-10123주), 락토바실러스 DSM 2024주(Lactobacillus DSM 2024주), 락토바실러스 플란타룸 ATCC 14947주(Lactobacillus, plantarum ATCC 14947주) 및 비피도박테리움 비피둠 JCM 7002주(Bifidobacterium bifidum JCM 7002주) 중 1종 이상일 수 있다.Lactobacillus casei strain FERM BP-10123 strain), Lactobacillus DSM 2024 strain (Lactobacillus strain DSM 2024 strain), Lactobacillus planta ATCC 14947 strain (Lactobacillus plantarum strain, ATCC 14947 strain) and Bifidobacterium bifidum JCM 7002 strain (Bifidobacterium bifidum JCM 7002 strain).
락토바실러스 카제이 하세가와 FERM BP-10123주(Lactobacillus casei strain Hasegawa FERM BP-10123주)는 김치 및 절임식품으로부터 분리 및 동정한 락토바실러스 카제이 속의 신규한 균주이다.Lactobacillus casei strain Hasegawa FERM BP-10123 strain is a novel strain of Lactobacillus casei isolated from kimchi and pickled foods.
락토바실러스 카제이 하세가와 FERM BP-10123주(Lactobacillus casei strain Hasegawa FERM BP-10123주)는 인삼(Panax)속 식물의 유효성분인 진세노사이드(ginsenoside)를 기질로 하여 가수분해물, 즉 상기한 FGM1 및 FGM4을 생성하는 것을 특징으로 한다.The Lactobacillus casei strain Hasegawa FERM BP-10123 strain (Lactobacillus casei strain FERM BP-10123 strain) was prepared by using ginsenoside, an active ingredient of Panax spp., As a substrate and hydrolyzate, Thereby generating FGM4.
락토바실러스 DSM 2024주(Lactobacillus DSM 2024주), 락토바실러스 플란타룸 ATCC 14947주(Lactobacillus, plantarum ATCC 14947주) 및 비피도박테리움 비피둠 JCM 7002주(Bifidobacterium bifidum JCM 7002주)는 사포닌 분해능이 있는 균주로, 활성이 높아 가장 바람직하나, 사포닌 분해능이 있는 균주들도 사용될 수 있다.Lactobacillus DSM 2024 strain (Lactobacillus DSM 2024 strain), Lactobacillus planta ATCC 14947 strain (Lactobacillus plantarum ATCC 14947 strain) and Bifidobacterium bifidum JCM 7002 strain (Bifidobacterium bifidum JCM 7002 strain) As a strain, it is most preferable since activity is high, but strains having saponin-decomposing ability can also be used.
이와 같이 조합발효균주로 인삼을 발효시키는 것은 단일 균주로 배양시키는 것보다 배양시간을 단축시키고, 조합하는 균주의 종류와 비율에 따라 얻어지는 추출물의 진세노이드 종류와 함량에 크게 영향을 미친다.Thus, fermentation of ginseng mainly by combination fermentation broth largely affects the type and content of ginsenosides of the extract obtained according to the types and ratios of the strains to be combined, as compared with culturing the ginseng with a single strain.
여기에서는 사포닌의 당유도체를 쉽게 끊어내는 것으로 알려진 균주들을 조합하여 활용하였다.Here, strains known to easily break off sugar derivatives of saponin were used in combination.
인삼은 고려인삼, 고려흑삼, 고려홍삼 및 삼양삼 중 하나일 수 있고, 분말형태일 수 있다.The ginseng may be one of Korean ginseng, Korean black ginseng, Korean red ginseng and Samyang ginseng, and may be in powder form.
상기와 같은 발효인삼은 발효 후 별도의 정제없이 그 자체로 섭취가능하며, 풍미 및 인지기능개선 효과가 우수하다.Such fermented ginseng can be ingested by itself without further purification after fermentation, and has excellent flavor and cognitive function improving effect.
이러한 발효인삼과 인지기능개선 약재군 추출물(발효 추출물)을 조합하면 장에서 흡수가 용이한 인지기능개선용 조성물을 제조할 수 있다.When such fermented ginseng and the cognitive function improving drug group extract (fermentation extract) are combined, it is possible to prepare a composition for improving cognition which is easily absorbed in the intestines.
하기에서 인지기능개선용 조성물을 구체적으로 설명하기로 한다.Hereinafter, the composition for improving the cognitive function will be specifically described.
본 발명의 제1 실시예에 따른 인지기능개선용 조성물은 발효인삼을 포함할 수 있다.The composition for improving the cognitive function according to the first embodiment of the present invention may include fermented ginseng.
또한, 본 발명의 제1 실시예에 따른 인지기능개선용 조성물은 인지기능개선 약재군 추출물을 더 포함할 수 있다.In addition, the composition for improving the cognitive function according to the first embodiment of the present invention may further comprise a cognitive function improving drug group extract.
이와 같이, 인지기능개선용 조성물은 발효인삼에 인지기능개선 약재군 추출물이 배합되어 인지기능개선 효과가 더욱 향상될 수 있다.As described above, the composition for improving the cognitive function can further improve the cognitive function improving effect by combining the cognitive function improving drug group extract with the fermented ginseng.
발효인삼은 상기에서 설명한 본 발명의 제1 실시예에 따른 발효인삼과 실질적으로 동일하므로 생략하기로 한다.The fermented ginseng is substantially the same as the fermented ginseng according to the first embodiment of the present invention described above and will not be described.
인지기능개선 약재군 추출물은 인지기능개선 약재군을 발효시켜 제조한 것으로, 인지기능개선 약재군은 원지, 복령, 참당귀, 은행잎, 오미자, 창포, 지황, 천마, 도라지, 모렐버섯 및 황기 중 하나일 수 있다.The cognitive function improving drug group was prepared by fermenting the cognitive function improving drug group, and the cognitive function improving drug group was one of the raw materials such as raw paper, gyeongryeong, ginseng, ginkgo leaf, omija, iris, Lt; / RTI >
인지기능개선 약재군 추출물은 인지기능개선 약재군 및 증류수를 혼합하고 살균한 후 조합발효균주를 접종하여 발효시키는 것으로 제조될 수 있다.The cognitive function improving drug group extract may be prepared by mixing and curing the cognitive function improving drug group and distilled water, and then inoculating a combination fermentation strain to ferment.
인지기능개선 약재군의 2 내지 5배인 증류수를 혼합하고, 인지기능개선 약재군 전체 중량%에 대하여 2 내지 10%로 조합발효균주를 접종하고 25 내지 40℃에서 5 내지 20일동안 배양하였다.Distilled water in an amount of 2 to 5 times that of the cognitive function improving drug group was mixed and the combination fermentation strain was inoculated at 2 to 10% based on the total weight% of the cognitive function improving drug group and cultured at 25 to 40 DEG C for 5 to 20 days.
이때, 조합발효균주는 본 발명의 제1 실시예에 따른 발효인삼에서 사용한 조합발효균주와 동일한 것으로, 조합발효균주는 인삼(Ginseng Radix)의 진세노사이드(ginsenoside) 이외에도 감초의 글리시리진(glycyrrhizin), 작약(Paeoniae Radiz)의 패오니플로린(paeoniflorin), 시호의 사이코사포닌(saikosaponin), 황금(Scutellariae Radix)의 바이칼린(baicalin), 대황(Rhei Rhizoma)의 센노사이드(sennoside), 산치자(Gardeniae Fructus)의 제니포사이드(geniposide), 대두의 이소플라본(isoflavone), 원지(Polygalae Radix)의 온지사포닌(onjisaponin) 등의 배당체 및 나무껍질, 잎, 모렐버섯 등의 버섯 등의 세포섬유도 가수분해하는 특징을 가지므로 약용 천연물 발효에도 유익하다.The combination fermenting bacteria are the same as the combination fermentation bacteria used in the fermented ginseng according to the first embodiment of the present invention. In addition to the ginsenoside of ginseng radix, the combination fermenting bacteria may be glycyrrhizin, Paeoniflorin of Paeoniae Radiz, saikosaponin of Shiho, baicalin of Scutellariae Radix, sennoside of Rhei Rhizoma, jenny of Gardeniae Fructus, Since it has the characteristic of hydrolyzing cellulosic materials such as geniposide, soy isoflavone, glycosides such as polygalae radix onjisaponin, and mushroom such as bark, leaf, and morel mushroom It is also beneficial for fermentation of medicinal natural products.
인지기능개선용 조성물은 상기에 나타낸 바와 같이 인지기능개선 약재군 추출물(발효 추출물) 및 발효인삼을 배합하여 제조될 수 있다. The composition for improving the cognitive function may be prepared by blending a cognitive function improving drug group extract (fermented extract) and fermented ginseng as described above.
또한, 인지기능개선용 조성물은 인지기능개선용 조성물 전체 중량에 대하여, 발효인삼 10 내지 80 중량% 및 인지기능개선 약재군 추출물 90 내지 20 중량%를 포함할 수 있다.In addition, the composition for improving the cognitive function may comprise 10 to 80% by weight of fermented ginseng and 90 to 20% by weight of the cognitive function improving drug group extract, based on the total weight of the composition for improving cognitive function.
또한, 본 발명의 제1 실시예에 따른 인지기능개선용 조성물은 과실액 및 벌꿀 중 하나 이상을 더 포함할 수 있고, 제품의 풍미, 소비자 기호 및 영양성분 보충을 위하여 과실액 및 벌꿀을 포함하는 것이 가장 바람직하다.In addition, the composition for improving the cognitive function according to the first embodiment of the present invention may further include at least one of a fruit solution and a honey, and it may contain at least one of a fruit solution and a honey for supplementing the flavor, Is most preferable.
여기서 과실액은 유자, 레몬 및 감귤을 착즙하고 농축하여 제조될 수 있다.Here, the fruit juice can be prepared by juicing and concentrating citron, lemon and citrus fruit.
유자는 감의 2배, 레몬의 3배, 바나나의 10배로 비타민C가 풍부한여 감기예방에 좋다. 또한 해열, 소염, 진해 작용에도 도움이 된다. Yuzu is twice as good as the persimmon, three times as lemon, ten times as much as banana, and it is good for prevention of cold which is rich in vitamin C. It also helps with fever, inflammation and dermatitis.
유자의 리모넨 성분은 목의 염증을 가라앉히는 데에 좋고, 리모넨 성분은 또한 펙틴 성분과 함께 모세혈관을 건강하고 튼튼하게 해 혈액 순환에도 도움이 된다. Citron's limonene is good for relieving the inflammation of the neck, and the limonene ingredient also helps the blood circulation by making the capillaries healthy and strong with the pectin ingredient.
유자 속 헤스페레딘 성분은 뇌혈관 장애 예방과 혈압 조절에 효과를 볼 수 있다.The hesperidin ingredient in citron can be effective in preventing cerebrovascular disorders and controlling blood pressure.
레몬은 몸 속 노폐물을 배출하는 데에도 탁월하다. 특히 동맥 정화에 탁월해 혈액 순환이 원활해지는 것은 물론 심혈관 질환 예방에 좋다. 나트륨 배출에도 도움이 돼 붓기 완화에도 뛰어나다. Lemons are also excellent for the waste of body waste. Especially excellent for arterial purification, blood circulation is smooth, as well as prevention of cardiovascular disease. It also helps in the discharge of sodium, which is also excellent for relieving swelling.
또한, 신맛이 강하지만 레몬은 의외로 우리 몸을 알칼리화하는데에 도움이 된다. pH 수치를 조절해 변비나 소화불량, 위산 과다 등 소화기 질환에도 효과를 발휘한다. 또한 레몬의 구연산이 자연적인 위산을 보충해 음식을 분해하는 것을 돕는다.Also, although sour is strong, lemon is surprisingly helpful in alkalizing our body. Adjust the pH level to exert its effects on gastrointestinal diseases such as constipation, indigestion, and gastric hyperplasia. Also, citric acid in lemons helps break down food by supplementing natural stomach acids.
귤의 하얀 실처럼 생긴 알베도는 혈압 관리에 뛰어나고, 알베도가 혈관을 건강하게 해준다.Albedo, like the white thread of mandarin, is excellent in blood pressure control, and albedo makes blood vessels healthy.
귤의 헤스페리딘 성분도 혈관 저항력을 증가시켜 고혈압을 예방하고, 페타크립토산틴은 항산화, 항염증 작용을 한다.Hesperidin component of mandarin also increases blood vessel resistance to prevent hypertension, and peta cryptosanthin acts antioxidant and anti-inflammatory.
또한, 최근엔 농촌진흥청과 제주대학교가 진행한 공동연구에선 감귤 추출물이 새로운 사물 인지 능력과 공간 인지 능력, 기억력 향상에 효과가 있다는 점을 동물실험을 통해 밝혀냈다Recently, in collaboration with the RDA and Cheju National University, it has been shown through animal experiments that citrus extracts are effective in improving new cognitive ability, spatial cognitive ability, and memory ability
벌꿀은 포도당, 과당, 자당, 녹말, 지방, 단백질, 방향족 화합물, 비타민, 무기염, 효소, 아미노산, 코린 등 많은 영양분들을 함유하고 있다.Honey contains many nutrients such as glucose, fructose, sucrose, starch, fat, protein, aromatics, vitamins, inorganic salts, enzymes, amino acids,
이에 따라, 벌꿀은 신진대사를 활발하게 하고 피로를 회복시켜 줄 수 있다.As a result, honey can stimulate metabolism and restore fatigue.
이때, 인지기능개선용 조성물은 인지기능개선용 조성물 전체 중량에 대하여, 과실액 0.2 내지 0.9 중량% 및 벌꿀 0.1 내지 0.5중량%를 더 포함할 수 있다.At this time, the composition for improving the cognitive function may further comprise 0.2 to 0.9% by weight of fruit juice and 0.1 to 0.5% by weight of honey, based on the total weight of the composition for improving cognitive function.
이에 따라, 인지기능개선 조성물은 맛이 향상되고, 농축액 형태로 제조할 수 있다.Accordingly, the cognitive function improving composition can be improved in taste and can be produced in the form of a concentrate.
또한, 과실액 및 벌꿀을 포함할 경우 과실액의 신맛을 벌꿀이 보완해줄 수 있다. In addition, when fruit juice and honey are included, honey can complement the sour taste of fruit juice.
또한, 본 발명의 제1 실시예에 따른 인지기능개선용 조성물은 비타민을 더 포함할 수 있다.In addition, the composition for improving the cognitive function according to the first embodiment of the present invention may further include vitamins.
비타민은 비타민 C 및 활성비타민 B군으로 이루어질 수 있고, 인지기능개선용 조성물 전체 중량에 대하여, 비타민 C(Vitamin C), 비타민 B1(Vitamin B1), 비타민 B2(Vitamin B2), 비타민 B6(Vitamin B6) 및 비타민 B12(Vitamin B12) 를 포함하는 것이며 비타민 B 군은 활성비타민으로 조성하는 것이 바람직하다.The vitamins may be composed of vitamin C and active vitamin B group and may be selected from the group consisting of vitamin C, vitamin B1, vitamin B2, vitamin B6, ) And vitamin B12 (vitamin B12), and the vitamin B group is preferably composed of active vitamins.
또한, 비타민은 인지기능개선용 조성물 전체 중량에 대하여, 2 내지 8중량%를 포함할 수 있다.In addition, the vitamin may contain 2 to 8% by weight based on the total weight of the composition for improving cognitive function.
여기서 비타민 C는 항산화(항노화) 작용을 할 수 있고, 활성비타민 B군은 노령의 인체에 생리활력증진 효과를 줄 수 있다.Here, vitamin C can act as an antioxidant (anti-aging), and the active vitamin B group can enhance the physiological activity of the aged human body.
또한, 본 발명의 제1 실시예에 따른 인지기능개선용 조성물은 모랑가잎 추출물을 더 포함할 수 있다.In addition, the composition for improving the cognitive function according to the first embodiment of the present invention may further comprise a Moranganga leaf extract.
모랑가잎 추출물은 모랑가잎으로 제조된 것으로, 모랑가잎은 콩과식물로 알려진 모랑가의 잎으로 모랑가는 전체적으로 영양성분이 풍부하고 모랑가잎에 가장 많이 함유되어 있다.The Moranganga leaf extract is made with Morangga leaves. The Moranganga leaves are the leaves of Morangaga, known as the legumes, and are generally abundant in nutrients and are most abundant in Moranganga leaves.
모랑가잎은 비타민C, A, 칼륨, 폴리페놀, 단백질 등이 풍부하고, 피부미용, 다이어트, 혈압강하, 피로회복, 모발건강에 도움을 주는 효과 등을 가지고 있다.Moranganga leaf is rich in vitamin C, A, potassium, polyphenol, and protein, and has effects such as skin aesthetics, diet, blood pressure reduction, fatigue recovery, and hair health.
또한, 모랑가잎은 칼슘이 풍부하여 두통과 편두통에 도움을 줄 수 있다.In addition, Morangaga leaf is rich in calcium, can help with headache and migraine.
또한, 모랑가잎은 플라보노이드, 항토시아닌, 라이코펜 등과 같은 항산화물질이 풍부하여, 항산화 작용을 할 수 있다.In addition, Morangaga leaf is rich in antioxidant substances such as flavonoids, antitocinian, lycopene, etc., and is capable of antioxidative action.
이러한 모랑가잎으로 제조되는 모랑가잎 추출물은 건조시킨 모랑가잎을 분쇄하는 단계, 분쇄된 모랑가잎을 물에 담긴 용기에 투입하고 용기에 기포기를 이용하여 산소를 공급하여 상온(20 내지 25℃)에서 4주 내지 5주동안 1차 발효시키는 단계 및 1차 발효된 모랑가잎에 조합발효균주를 모랑가잎 전체 중량%에 대하여 1 내지 5%로 접종한 후 25 내지 30℃에서 3주 내지 4주 동안 2차 발효시키는 단계로 제조될 수 있다.The Morangaga leaf extract, which is produced from the Moranganga leaves, is prepared by pulverizing dried Morangaga leaves, introducing the pulverized Morangao leaves into a container filled with water, supplying oxygen to the container using a bubbler, A primary fermentation for 1 to 5 weeks, and a primary fermentation with a combination fermentation strain in an amount of 1 to 5% based on the total weight percentage of the leaves of Moranganthae, and then inoculated at 25 to 30 DEG C for 3 to 4 weeks for a secondary Followed by fermentation.
모랑가잎 추출물은 상기와 같은 방법으로 제조되어 모랑가잎의 유효성분이 추출되도록 할 수 있다.The Morana leaf extract can be produced by the above-mentioned method so that the active ingredient of Morana leaf can be extracted.
또한, 모랑가잎 추출물은 인지기능개선용 조성물 전체 중량에 대하여, 10 내지 15중량%를 포함할 수 있다.In addition, the Morandi leaf extract may contain 10 to 15% by weight based on the total weight of the composition for improving cognitive function.
이러한 모랑가잎 추출물은 인지기능개선용 조성물에 함유되어 피로회복, 항산화 작용, 두통 및 편두통 완화 등의 작용을 할 수 있다.Such Moranganthae leaf extract is contained in a composition for improving cognitive function and can perform actions such as fatigue recovery, antioxidative action, headache and migraine relief.
또한, 인지기능개선용 조성물은 분말, 과립, 환, 음료 및 농축액 중 하나의 형태로 제조될 수 있고, 분말 또는 농축액 형태로 제조되는 것이 가장 바람직하다.Furthermore, the composition for improving the cognitive function may be prepared in the form of a powder, a granule, a ring, a beverage and a concentrate, most preferably in the form of a powder or a concentrate.
이는 분말 또는 농축액 형태로 제조될 경우, 복용시 부작용이 적고 효능이 증강될 수 있다.When manufactured in the form of a powder or concentrate, the side effects are small and the efficacy can be enhanced upon administration.
또한, 인지기능개선용 조성물은 복용 편리성 향상을 위하여 캡슐을 이용하여 캡슐 형태로 제조될 수 있다.In addition, the composition for improving the cognitive function may be prepared in the form of a capsule using capsules for improving the convenience of taking.
상기에서 설명한 바와 같이 인지기능개선용 조성물은 인삼을 조합발효균주로 발효하여 제조된 발효인삼에 인지기능개선 약재군 추출물, 과실액, 벌꿀 및 활성비타민을 첨가하는 것으로 제조할 수 있으며, 발효전 인삼 및 인지기능개선 약재군을 혼합하여 조합발효균주로 동시에 발효시키고 과실액, 벌꿀은 제품화 단계에서 풍미조절용으로, 비타민은 생리활성 도움용으로 첨가할 수 있다.As described above, the composition for improving the cognitive function can be prepared by adding a cognitive function improving drug group extract, a fruit solution, a honey, and an active vitamin to fermented ginseng produced by fermenting mainly ginseng with a combination fermenting microorganism, The cognitive function improvement medicines are mixed and fermented mainly in combination with the fermentation broth. Fruit juice and honey can be added for flavor control at the commercialization stage, and vitamins can be added for physiological activity.
이와 같은 인지기능개선용 조성물에 대하여 하기에서 설명하기로 한다.The composition for improving the cognitive function will be described below.
또한, 본 발명의 제2 실시예에 따른 인지기능개선용 조성물은 인삼 및 인지기능개선 약재군을 혼합하고 사카로미세스 세레비시아(Saccaharomyces cerevisiae S6-1, KACC93225P)와 식이용 발효균주를 조합한 조합발효균주를 접종하고 배양하여 얻어진 인지기능개선용 조성물을 제공할 수 있다.In addition, the composition for improving the cognitive function according to the second embodiment of the present invention is prepared by mixing ginseng and a cognitive function improving drug group, combining Saccaharomyces cerevisiae S6-1 (KACC93225P) with a food-use fermentation strain A composition for cognitive function improvement obtained by inoculating and culturing a combination fermentation strain can be provided.
인삼은 본 발명의 제1 실시예와 동일하므로 자세한 설명은 생략한다.Since ginseng is the same as the first embodiment of the present invention, detailed description thereof will be omitted.
인지기능개선 약재군은 본 발명의 제1 실시예와 동일하므로 자세한 설명은 생략한다.The cognitive function improving medicament group is the same as the first embodiment of the present invention, and thus a detailed description thereof will be omitted.
여기서, 인삼 및 인지기능개선 약재군은 인지기능개선용 조성물 전체 중량에 대하여, 발효인삼 10 내지 80 중량% 및 인지기능개선 약재군 90 내지 20 중량%을 혼합할 수 있다.Here, the ginseng and cognitive function improving drug group may be mixed with 10 to 80% by weight of fermented ginseng and 90 to 20% by weight of the cognitive function improving drug group, based on the total weight of the composition for improving cognitive function.
혼합된 인삼 및 인지기능개선 약재군에 사카로미세스 세레비시아(Saccaharomyces cerevisiae S6-1, KACC93225P)와 식이용 발효균주를 조합한 조합발효균주를 접종하여 발효시킬 수 있다.Fermentation can be carried out by inoculating a combination fermentation strain obtained by combining Saccharomyces cerevisiae S6-1, KACC93225P and a food-borne fermentation strain in the mixed ginseng and cognitive function improving drug substance groups.
이때, 혼합된 인삼 및 인지기능개선 약재군이 배지이고, 혼합된 인삼 및 인지기능개선 약재군을 혼합된 인삼 및 인지기능개선 약재군 중량 2 내지 8배의 증류수에 넣고 살균처리한 후 조합발효균주를 혼합된 인삼 및 인지기능개선 약재군 전체 중량%에 대하여 2 내지 20%로 접종하고 25 내지 45℃에서 1 내지 4주동안 배양하여 인지기능개선용 조성물을 제조할 수 있다.In this case, the mixed ginseng and the cognitive function improving drug group are the medium, and the mixed ginseng and the cognitive function improving drug group are put into the mixed ginseng and the cognitive function improving drug group in the weight of 2 to 8 times of distilled water, To 2 to 20% based on the total weight% of the mixed ginseng and cognitive function improving drug group and incubating the mixture at 25 to 45 캜 for 1 to 4 weeks to prepare a composition for improving cognitive function.
또한, 본 발명의 제2 실시예에 따른 인지기능개선용 조성물은 발효 후 과실액 및 벌꿀 중 하나 이상을 더 포함할 수 있고, 과실액 및 벌꿀을 포함하는 것이 바람직하며, 풍미를 위하여 인지기능개선용 조성물 전체 중량에 대하여, 과실액 및 벌꿀을 0.2 내지 0.7중량%를 포함하는 것이 바람직하다.In addition, the composition for improving the cognitive function according to the second embodiment of the present invention may further comprise at least one of fruit juice and honey after fermentation, and preferably includes fruit juice and honey, And 0.2 to 0.7% by weight of a fruit solution and honey, based on the total weight of the composition.
이러한 과실액 및 벌꿀의 구성은 본 발명의 제1 실시예와 동일하므로 자세한 설명은 생략한다.Since the constitution of such fruit liquid and honey is the same as that of the first embodiment of the present invention, detailed description is omitted.
또한, 본 발명의 제2 실시예에 따른 인지기능개선용 조성물은 발효 후 비타민을 더 포함할 수 있다.In addition, the composition for improving the cognitive function according to the second embodiment of the present invention may further contain vitamins after fermentation.
이러한 비타민은 본 발명의 제1 실시예와 동일하므로 자세한 설명은 생략한다.Since these vitamins are the same as the first embodiment of the present invention, detailed description is omitted.
또한, 본 발명의 제2 실시예에 따른 인지기능개선용 조성물은 발효 후 모랑가잎 추출물을 더 포함할 수 있다.In addition, the composition for improving the cognitive function according to the second embodiment of the present invention may further comprise a Morangi leaf extract after fermentation.
이러한 모랑가잎 추출물은 본 발명의 제1 실시예와 동일하므로 자세한 설명은 생략한다.Since the extract of Morgana leaves is the same as that of the first embodiment of the present invention, detailed description thereof will be omitted.
또한, 인지기능개선용 조성물은 분말, 과립, 환, 음료 및 농축액 중 하나의 형태로 제조될 수 있고, 분말 또는 농축액 형태로 제조되는 것이 가장 바람직하다.Furthermore, the composition for improving the cognitive function may be prepared in the form of a powder, a granule, a ring, a beverage and a concentrate, most preferably in the form of a powder or a concentrate.
이는 분말 또는 농축액 형태로 제조될 경우, 복용시 부작용이 적고 효능이 증강될 수 있다.When manufactured in the form of a powder or concentrate, the side effects are small and the efficacy can be enhanced upon administration.
또한, 인지기능개선용 조성물은 캡슐을 이용하여 캡슐 형태나 파우치 형태로도 제조될 수 있다.In addition, the composition for improving the cognitive function may be prepared in the form of a capsule or a pouch using a capsule.
이에 따라, 복용 편리성이 향상될 수 있다.Thus, the convenience of taking can be improved.
이하, 하기의 다수의 실험 예를 통하여 조합발효균주를 이용한 발효인삼, 인지기능개선 약재군 추출물, 인지기능개선용 조성물을 구체적으로 설명한다.Hereinafter, the fermented ginseng, the cognitive function improving medicinal group extract and the composition for improving the cognitive function using the combination fermentation strain will be described in detail through the following experiment examples.
또한, 실시되는 실험 예들은 이해를 돕기 위하여 제시되는 것으로서, 본 발명을 예시하는 것일 뿐 본 발명의 권리범위가 하기 실험 예들에 한정되는 것은 아니며, 실험의 주요 시료인 인삼과 인지기능개선 약재군의 형태(생재료, 건재료, 분말재료 등)에 한정되지 않는다.It is to be understood that the scope of the present invention is not limited to the following examples and that the scope of the present invention is not limited to the following examples, Shape (raw material, dry material, powder material, etc.).
[실시예 1][Example 1]
분말 형태인 고려인삼(배지)(대한민국산, 혹은 중국동북지역산, 건조 4~6년근) 2kg를 정제수 10L에 넣고 고압가열 살균한 후, 카로미세스 세레비시아(Saccaharomyces cerevisiae S6-1, KACC93225P), 락토바실러스 플란타룸 ATCC 14947주(Lactobacillus, plantarum ATCC 14947주) 및 비피도박테리움 비피둠 JCM 7002주(Bifidobacterium bifidum JCM 7002주)를 조합한 조합발효균주를 고려인삼 전체 중량%에 대하여 1중량%를 접종하여 35℃에서 2주간 배양하여 발효인삼을 제조하였다.2 kg of Korean ginseng powder (in Korean or Chinese northeastern region) was put into 10 L of purified water and sterilized by heating under high pressure. Then, Saccaharomyces cerevisiae S6-1, KACC93225P, , Lactobacillus plantarum ATCC 14947 strain (Lactobacillus plantarum ATCC 14947 strain) and Bifidobacterium bifidum JCM 7002 strain (Bifidobacterium bifidum JCM 7002 strain) were mixed with 1 g % And incubated at 35 ° C for 2 weeks to prepare fermented ginseng.
[실시예 2][Example 2]
고려인삼 대신 분말 형태인 고려흑삼(배지)(대한민국산, 건조 4~6년근) 2kg을 사용한 것을 제외하고 실시예 1과 동일하게 제조하였다.Except that 2 kg of Korean black ginseng (culture medium, manufactured by Korea, dried 4-6 years old) in powder form instead of Korean ginseng was used.
[실시예 3][Example 3]
고려인삼 대신 분말 형태인 고려홍삼(배지)(대한민국산) 2kg을 사용한 것을 제외하고 실시예 1과 동일하게 제조하였다.Example 2 was prepared in the same manner as in Example 1, except that 2 kg of Korean red ginseng (medium) (Korea) (ginseng powder) instead of Korean ginseng was used.
[비교예 1][Comparative Example 1]
인삼에 락토바실러스균을 접종한 것을 제외하고 실시예 1과 동일하게 제조하였다.The same procedure as in Example 1 was conducted except that lactobacillus was inoculated into ginseng.
[비교예 2][Comparative Example 2]
인삼에 누룩균을 접종한 것을 제외하고 실시예 1과 동일하게 제조하였다.The same procedure as in Example 1 was conducted except that ginseng was inoculated with ginseng.
[비교예 3][Comparative Example 3]
인삼에 유산균을 접종한 것을 제외하고 실시예 1과 동일하게 제조하였다.The same procedure as in Example 1 was carried out except that the ginseng was inoculated with the lactic acid bacteria.
[비교예 4][Comparative Example 4]
홍삼분말에서 구증구포의 전통방법으로 얻어진 추출물을 제조하였다.The red ginseng powder was prepared by the conventional method.
[[ 실험예Experimental Example 1] 발효인삼의 생물전환 확인 1] Confirmation of bio-conversion of fermented ginseng
실시예 1(고려인삼)을 3000rpm에서 10분간 원심분리하여 얻어진 상층액 2μL를 TLC 플레이트(kiesel gel 60F254, merck)에 점적하고 동시에 사포닌 분해물 표준물질로서 FGM1 및 FGM4도 점적한 후, TLC 혼합용매(클로로포름-메탄올-물=60:35:10, 하층)로 전개하였으며, TLC 플레이트에 8% 바닐린-메탄올(vanillin-methanol)과 72% 황산용액을 1:5(용적비)로 혼합한 용액을 분무하고 120℃에서 2분간 가열하여 적자색을 나타내는 반점을 검출하였다.2 μL of the supernatant obtained by centrifuging Example 1 (Korean ginseng) at 3000 rpm for 10 minutes was dispensed on a TLC plate (kiesel gel 60F254, merck), and FGM1 and FGM4 were also spotted as standard saponin degradation products. The mixture was developed by spraying a solution prepared by mixing 8% vanillin-methanol and 72% sulfuric acid solution in a volume ratio of 1: 5 (volume ratio) to a TLC plate And heated at 120 DEG C for 2 minutes to detect a spot showing reddish purple color.
이에 따라, 실시예 1의 발효인삼은 인삼의 사포닌이 FGM1 및 FGM4로 생물전환된 것을 확인할 수 있었다.Accordingly, it was confirmed that the fermented ginseng of Example 1 was bioconverted to FGM1 and FGM4 by saponin of ginseng.
[[ 실험예Experimental Example 2] 2] HPLCHPLC -MS/MS 분석-MS / MS analysis
실시예 2(고려흑삼)의 하기 표 1에 도시된 HPLC-MS/MS 시스템의 분석 조건에 따라 HPLC-MS/MS 분석을 실시하였다.HPLC-MS / MS analysis was carried out according to the analytical conditions of HPLC-MS / MS system shown in Table 1 of Example 2 (Korean black ginseng).
A : H2O (0.2% formic acid/0.04% ammonia)
B : CANMovement phase
A: H 2 O (0.2% formic acid / 0.04% ammonia)
B: CAN
실시예 2의 발효인삼(고려흑삼)의 HPLC-MS/MS 분석 결과는 도 1과 같다.The HPLC-MS / MS analysis results of fermented ginseng (Korean black ginseng) of Example 2 are shown in FIG.
도 1은 실시예 2의 발효인삼(고려흑삼)의 HPLC-MS/MS 분석 그래프로, Rg1, Rg2, Rg3, Rb1, C-K 등의 기능성분과 함께 다양한 진세노사이드 패턴이 얻어진 것을 확인할 수 있다.1 is an HPLC-MS / MS analysis graph of fermented ginseng (Korean black ginseng) of Example 2, showing various ginsenoside patterns together with functional ingredients such as Rg 1 , Rg 2 , Rg 3 , Rb 1 and CK .
[[ 실험예Experimental Example 3] TLC 분석 및 크로마토그램 3] TLC analysis and chromatogram
실시예 2(고려흑삼, B) 및 표준품 혼합물(S), 홍삼추출물 A지역(1), 홍삼추출물 B지역(2), 홍삼추출물 C지역(3), 건삼(4), 백삼(5)의 성분을 TLC로 분석하였다.(1), red ginseng extract (2), red ginseng extract (3), red ginseng (4), white ginseng (5) The components were analyzed by TLC.
이때, 표준품 혼합물(S)는 진안에서 구입하여 확보한 진세노사이드 표준품의 혼합체이고, 홍삼추출물 A(1)는 진안, 홍삼추출물 B(2)는 금산, 홍삼추출물 C(3)는 부여, 건삼(4)은 금산, 백삼(5)은 금산에서 구입한 것을 처리한 것이다.In this case, the standard product mixture (S) is a mixture of ginsenoside standard products purchased and purchased from Jinan. The red ginseng extract A (1) is classified as Jinan, the red ginseng extract B (2) (4), and Jangsan (5) were purchased from Geumsan.
또한, 건삼(4), 백삼(5)은 시중에서 구입한 것을 분말로 만들어 메탄올(70%)과 증류수(30%)의 혼합용매로 추출하여 사용하였다.In addition, the dried ginseng (4) and white ginseng (5) were purchased from the market as powder and extracted with a mixed solvent of methanol (70%) and distilled water (30%).
TLC 분석 결과는 도 2와 같이 나타났다. The results of the TLC analysis were shown in Fig.
도 2는 실시예 2(B) 및 표준품 혼합물(S), 홍삼추출물 A지역(1), 홍삼추출물 B지역(2), 홍삼추출물 C지역(3), 건삼(4), 백삼(5)의 TLC 분석 결과를 나타낸 사진이다.FIG. 2 is a graph showing the results of the comparison between Example 2 (B) and the standard product mixture (S), red ginseng
도 3은 실시예 2(B)의 진세노사이드 함량에 대한 크로마토그램이다.3 is a chromatogram for the ginsenoside content of Example 2 (B).
도 2 및 도 3를 보면 알 수 있듯이, 실시예 2의 발효인삼(고려흑삼)의 기능성 진세노사이드 함량(Rg1 + Rg3 + Rb1)은 식약처기준 2.5~34 mg/g에 비하여 84~85 mg/g으로 매우 우수한 기능성을 나타내었다.2 and 3, the functional ginsenoside content (Rg 1 + Rg 3 + Rb 1 ) of fermented ginseng (Korean black ginseng) of Example 2 was 84 (mg / g) ~ 85 mg / g.
[[ 실험예Experimental Example 4] 진세노사이드 함량 비교 4] ginsenoside content comparison
실시예 3(고려홍삼) 및 비교예 1 내지 4의 진세노이드 함량을 측정하여 비교하였다.The content of ginsenosides of Example 3 (Korean red ginseng) and Comparative Examples 1 to 4 was measured and compared.
진세노이드 함량 측정 결과는 하기 표 2와 같다.The results of ginsenoside content measurement are shown in Table 2 below.
(식약처 기능성원료 요건: 기능성분의 함량으로 Rb1+Rg1+Rg3(s) = 2.5~34mg/g 이상 함유된 경우: 면역력증진, 피로개선, 혈소판응집 억제를 통한 혈액흐름, 기억력개선, 항산화에 도움을 줄 수 있음)(Rb 1 + Rg 1 + Rg 3 (s) = 2.5 to 34 mg / g or more based on the content of the functional ingredient: Improvement of immune system, improvement of fatigue, inhibition of platelet aggregation, , May help antioxidants)
상기 표 2를 보면 알 수 있듯이, 실시예 3의 Rb1+Rg1+Rg3(s)= 84.61 mg/g로 비교예 1(8.5mg/g), 비교예2(8.94mg/g), 비교예3(4.59+>0.1mg/g), 비교예 4(16.64mg/g)보다 Rb1+Rg1+Rg3(s)의 함량이 높다는 것을 확인할 수 있었다.As can be seen from the above Table 2, in Comparative Example 1 (8.5 mg / g), Comparative Example 2 (8.94 mg / g), and Rb 1 + Rg 1 + Rg 3 It was confirmed that the content of Rb 1 + Rg 1 + Rg 3 (s) was higher than that of Comparative Example 3 (4.59+> 0.1 mg / g) and Comparative Example 4 (16.64 mg / g).
따라서, 실시예 3이 비교예 1 내지 4보다 인지기능개선 효과가 높다고 판단할 수 있다.Therefore, it can be judged that the cognitive function improving effect of Example 3 is higher than that of Comparative Examples 1 to 4.
[실시예 4] 인지기능개선용 조성물 제조(과립)[Example 4] Preparation of composition for improving cognitive function (granule)
실시예 1의 발효인삼 500g및 인지기능개선 약재군 추출물 500g를 혼합하고, 동결 건조하여 분말을 수득한 후, 과실액 21g 및 벌꿀 24g, 비타민C 14g, 요구르트 향료 5g을 혼합하고, 전체 중량의 35%의 물을 첨가한 후 제립 및 건조하여 과립 형태의 인지기능개선용 조성물을 제조하였다.500 g of the fermented ginseng of Example 1 and 500 g of the cognitive function improving drug group extract were mixed and lyophilized to obtain a powder. 21 g of the fruit solution, 24 g of honey, 14 g of vitamin C and 5 g of yogurt fragrance were mixed and the total weight of 35 % Water was added thereto, followed by granulation and drying to prepare a granular composition for improving cognitive function.
인지기능개선 약재군 추출물은 분말 형태인 원지 및 복령 1000g, 오미자 및 은행잎 1000g을 정제수 500mL에 넣고 고압가열 살균한 후, 카로미세스 세레비시아(Saccaharomyces cerevisiae S6-1, KACC93225P), 락토바실러스 DSM 2024주(Lactobacillus DSM 2024주) 및 락토바실러스 플란타룸 ATCC 14947주(Lactobacillus, plantarum ATCC 14947주)를 조합한 조합발효균주를 인지기능개선 약재군 전체 중량%에 대하여 10중량%를 접종하여 30℃에서 2주간 배양하여 제조되었다.For the cognitive function improvement medicinal group extract, 1,000 g of raw ground ginseng and 1000 g of Omija and ginkgo leaf were put into 500 mL of purified water and sterilized by heating under high pressure. Then, Saccaharomyces cerevisiae S6-1, KACC93225P, Lactobacillus DSM 2024 (Lactobacillus DSM 2024 strain) and Lactobacillus plantarum ATCC 14947 strain (Lactobacillus plantarum ATCC 14947 strain) were inoculated at 10 wt% with respect to the total weight% of the cognitive function improving drug group, Lt; / RTI >
과실액은 유자, 레몬 및 귤을 착즙하고 농축하여 제조되었다.Fruit juice was prepared by juicing and concentrating citron, lemon and mandarin.
[실시예 5] 인지기능개선용 조성물 제조(분말)[Example 5] Composition for improving cognitive function (powder)
실시예 1의 발효인삼 1800g 및 인지기능개선 약재군 추출물 1800g를 혼합하고, 과실액 28g 및 벌꿀 20g을 첨가한 후 동결건조하여 분말형태의 인지기능개선용 조성물을 제조하였다.1800 g of the fermented ginseng of Example 1 and 1800 g of the cognitive enhancing drug group extract were mixed, and 28 g of fruit solution and 20 g of honey were added thereto and then lyophilized to prepare a powdery composition for improving cognitive function.
여기에서 과실액과 벌꿀의 첨가량은 풍미에 따라 가감할 수 있다.Here, the addition amount of the fruit solution and honey can be adjusted depending on the flavor.
[실시예 6] 인지기능개선용 조성물 제조(분말)[Example 6] Composition for improving cognitive function (powder)
분말 형태인 고려인삼(배지)(대한민국산, 혹은 중국동북지역산, 건조 4~6년근) 1,000g 및 인지기능개선 약재군 1000g를 정제수 3000mL에 넣고 고압가열 살균한 후, 카로미세스 세레비시아(Saccaharomyces cerevisiae S6-1, KACC93225P), 락토바실러스 DSM 2024주(Lactobacillus DSM 2024주) 및 락토바실러스 플란타룸 ATCC 14947주(Lactobacillus, plantarum ATCC 14947주)를 조합한 조합발효균주를 혼합한 인삼 및 인지기능개선 약재군 전체 중량%에 대하여 3%를 접종하여 30℃에서 2일간 배양한 후, 과실액 35g 및 벌꿀 15g을 첨가한 후 동결건조하여 분말 형태로 인지기능개선용 조성물을 제조하였다.1,000 g of powdered Koryo ginseng (Korean or Chinese northeastern mountain, dried 4-6 years old) and 1000 g of cognitive function improving medicine group were placed in 3000 mL of purified water, sterilized by heating under high pressure, and then sterilized by caromyces cerevisiae Saccaharomyces cerevisiae S6-1, KACC93225P), Lactobacillus DSM 2024 strain (Lactobacillus DSM 2024 strain) and Lactobacillus plantarum ATCC 14947 strain (Lactobacillus plantarum ATCC 14947 strain) 3% of the total weight of the improved medicament group was inoculated and cultured at 30 캜 for 2 days. Then, 35 g of fruit juice and 15 g of honey were added and lyophilized to prepare a composition for improving cognitive function in powder form.
인지기능개선 약재군은 은행잎, 복령, 오미자, 창포, 지황 및 모렐버섯이다.The medicines for improving cognitive function are ginkgo leaf, bokyeong, omija, iris, rhubarb and morel mushroom.
[실시예 7] 인지기능개선용 조성물 제조(음료)[Example 7] Preparation of composition for improving cognitive function (beverage)
분말 형태인 고려인삼(배지)(대한민국산, 혹은 중국동북지역산, 건조 4~6년근) 1,000g 및 인지기능개선 약재군 1000g를 정제수 3000mL에 넣고 고압가열 살균한 후, 카로미세스 세레비시아(Saccaharomyces cerevisiae S6-1, KACC93225P), 락토바실러스 DSM 2024주(Lactobacillus DSM 2024주) 및 락토바실러스 플란타룸 ATCC 14947주(Lactobacillus, plantarum ATCC 14947주)를 조합한 조합발효균주를 혼합된 인삼 및 인지기능개선 약재군 전체 중량%에 대하여 3%를 접종하여 30℃에서 2일간 배양한 후, 과실액 35g 및 벌꿀 15g을 첨가한 후 여과하여 여과액에 탄소가스를 충전하여 음료 형태의 인지기능개선용 조성물을 제조하였다.1,000 g of powdered Koryo ginseng (Korean or Chinese northeastern mountain, dried 4-6 years old) and 1000 g of cognitive function improving medicine group were placed in 3000 mL of purified water, sterilized by heating under high pressure, and then sterilized by caromyces cerevisiae Saccaharomyces cerevisiae S6-1, KACC93225P), Lactobacillus DSM 2024 strain (Lactobacillus DSM 2024 strain) and Lactobacillus plantarum ATCC 14947 strain (Lactobacillus plantarum ATCC 14947 strain) were mixed with ginseng and
[실시예 8] 인지기능개선용 조성물 제조(농축액)[Example 8] Preparation of composition for improving cognitive function (concentrate)
분말 형태인 고려인삼(배지)(대한민국산, 혹은 중국동북지역산, 건조 4~6년근) 1,000g 및 인지기능개선 약재군 1000g를 정제수 3000mL에 넣고 고압가열 살균한 후, 카로미세스 세레비시아(Saccaharomyces cerevisiae S6-1, KACC93225P), 락토바실러스 DSM 2024주(Lactobacillus DSM 2024주) 및 락토바실러스 플란타룸 ATCC 14947주(Lactobacillus, plantarum ATCC 14947주)를 조합한 조합발효균주를 혼합된 인삼 및 인지기능개선 약재군 전체 중량%에 대하여 3중량%를 접종하여 30℃에서 2일간 배양한 후, 과실액 35g 및 벌꿀 15g을 첨가한 후 농축하여 농축액 형태의 인지기능개선용 조성물을 제조하였다.1,000 g of powdered Koryo ginseng (Korean or Chinese northeastern mountain, dried 4-6 years old) and 1000 g of cognitive function improving medicine group were placed in 3000 mL of purified water, sterilized by heating under high pressure, and then sterilized by caromyces cerevisiae Saccaharomyces cerevisiae S6-1, KACC93225P), Lactobacillus DSM 2024 strain (Lactobacillus DSM 2024 strain) and Lactobacillus plantarum ATCC 14947 strain (Lactobacillus plantarum ATCC 14947 strain) were mixed with ginseng and
[실시예 9] 인지기능개선용 조성물 제조[Example 9] Composition for improving cognitive function
실시예 5에 비타민 4중량%를 더 첨가하는 것을 제외하고 실시예 5와 동일하게 제조하였다.Example 5 was prepared in the same manner as in Example 5, except that 4% by weight of the vitamin was further added.
[실시예 10] 인지기능개선용 조성물 제조[Example 10] Preparation of composition for improving cognitive function
실시예 6에 비타민 4중량%를 더 첨가하는 것을 제외하고 실시예 6와 동일하게 제조하였다.Example 6 was prepared in the same manner as in Example 6 except that 4% by weight of vitamin was further added.
[실시예 11] 인지기능개선용 조성물 제조[Example 11] Preparation of composition for improving cognitive function
실시예 5에 모랑가잎 추출물 10중량%를 더 첨가하는 것을 제외하고 실시예 6와 동일하게 제조하였다.Example 5 was prepared in the same manner as in Example 6, except that 10% by weight of Morgana leaf extract was further added.
모랑가잎 추출물은 건조시킨 모랑가잎을 분쇄한 후 분쇄된 모랑가잎을 물에 담긴 용기에 투입하고 용기에 기포기를 이용하여 산소를 공급하여 25℃에서 5주동안 1차 발효시키고, 1차 발효된 모랑가잎에 조합발효균주를 모랑가잎 전체 중량%에 대하여 1%로 접종한 후 30℃에서 4주 동안 2차 발효시켜 제조되었다.Morgana leaf extract was prepared by pulverizing dried Morgana leaves and then pulverizing Morangao leaves into a container filled with water. Oxygen was supplied to the container using a bubbler and the mixture was firstly fermented at 25 ° C for 5 weeks, The combination fermentation broth was prepared by inoculating the leaves with 1% of the total weight% of the Morana leaves and then fermenting at 30 ° C for 4 weeks.
[실시예 12] 인지기능개선용 조성물 제조[Example 12] Preparation of composition for improving cognitive function
실시예 6에 모랑가잎 추출물 10중량%를 더 첨가하는 것을 제외하고 실시예 6와 동일하게 제조하였다.Example 6 was prepared in the same manner as in Example 6, except that 10% by weight of Morangaga leaf extract was further added.
[[ 실험예Experimental Example 5] 관능검사 5] Sensory evaluation
상기 실시예 4 내지 12를 훈련된 전문 관능검사 요원(2년 이상 관능검사 경험을 지닌 50명[남자 25명, 여자 25명])중 미각이 상대적으로 우수한 30명을 선발하여 전체적인 맛, 향, 복용 후 느낌(복부느낌)으로 나누어 정량적 묘사분석(Quantitative Descriptive Analysis: QDA)을 하였다. 관능검사는 5점 측정법(1:매우 나쁨, 2:나쁨, 3:보통, 4:좋음, 5:매우 좋음)으로 실시하였다. 실시한 결과는 하기의 표 3에 나타내었다.Of the 50 persons (25 males and 25 females) who were trained in the above-mentioned Examples 4 to 12 and who had more than two years of experience in sensory testing, 30 persons with relatively good tastes were selected and the overall taste, And the feeling after taking (abdominal feelings), and performed quantitative descriptive analysis (QDA). The sensory evaluation was carried out by the 5-point method (1: very poor, 2: poor, 3: moderate, 4: good, 5: very good). The results are shown in Table 3 below.
상기 표 3에서 알 수 있듯이, 실시예 4 내지 12는 모든 항목에서 높은 점수를 받은 것을 확인할 수 있었다.As can be seen from the above Table 3, it can be confirmed that the Examples 4 to 12 were highly rated in all items.
이는 조합발효균주를 이용하여 발효시킴으로써 불쾌취 및 부작용을 일으키는 부산물이 발생하지 않아 발효 후 별도의 정제없이 조성물을 제조하여도 맛 및 향이 우수하고, 복부 통증 등을 유발하지 않아 복용 후 느낌도 우수하다고 판단할 수 있다.This is because fermentation using a combination fermentation strain does not produce unpleasant odors and by-products that cause side effects, so that even when a composition is prepared without further purification after fermentation, it has excellent taste and flavor, and does not cause abdominal pain, It can be judged.
이상으로 첨부된 도면을 참조하여 본 발명의 실시예를 설명하였으나, 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자는 본 발명의 기술적 사상이나 필수적인 특징을 변경하지 않고 다른 구체적인 형태로 실시할 수 있다는 것을 이해할 수 있을 것이다. 따라서 이상에서 기술한 실시예는 모든 면에서 예시적인 것이며 한정적이 아닌 것이다.While the present invention has been described in connection with what is presently considered to be practical exemplary embodiments, it is to be understood that the invention is not limited to the disclosed embodiments, but, on the contrary, You will understand. The embodiments described above are therefore to be considered in all respects as illustrative and not restrictive.
Claims (10)
Combined fermentation broth comprising ginseng combined with Saccharomyces cerevisiae S6-1 (KACC93225P) and fermented ginseng comprising FGM1 or FGM4 type fermented product obtained by biotransformation of a saponin glycoside moiety.
상기 인삼은,
고려인삼, 고려흑삼, 고려홍삼 및 삼양삼 중 하나인 것을 특징으로 하는 발효인삼.
The method according to claim 1,
The ginseng,
Korean ginseng, Korean black ginseng, Korean red ginseng and Samyang ginseng.
상기 식이용 발효균주는,
락토바실러스 카제이 하세가와 FERM BP-10123주(Lactobacillus casei strain Hasegawa FERM BP-10123주), 락토바실러스 DSM 2024주(Lactobacillus DSM 2024주), 락토바실러스 플란타룸 ATCC 14947주(Lactobacillus, plantarum ATCC 14947주) 및 비피도박테리움 비피둠 JCM 7002주(Bifidobacterium bifidum JCM 7002주) 중 1종 이상인 것을 특징으로 하는 발효인삼.
The method according to claim 1,
The above-
(Lactobacillus casei strain FERM BP-10123 strain), Lactobacillus strain DSM 2024 strain (Lactobacillus strain DSM 2024 strain), Lactobacillus plantarum ATCC 14947 strain (Lactobacillus plantarum ATCC 14947 strain) And Bifidobacterium bifidum JCM 7002 strain (Bifidobacterium bifidum JCM 7002 strain).
A composition for improving cognitive function comprising the fermented ginseng according to any one of claims 1 to 3.
상기 인지기능개선용 조성물은,
인지기능개선 약재군 추출물을 더 포함하는 인지기능개선용 조성물.
5. The method of claim 4,
The composition for improving the cognitive function,
A composition for improving cognitive function further comprising a cognitive function improving drug group extract.
상기 인지기능개선용 조성물은,
모랑가잎 추출물을 더 포함하는 인지기능개선용 조성물.
5. The method of claim 4,
The composition for improving the cognitive function,
A composition for improving cognitive function further comprising a Morangia leaf extract.
A composition for improving cognitive function, obtained by inoculating and culturing a combination fermentation strain obtained by mixing ginseng and a cognitive function improving drug group and combining Saccaharomyces cerevisiae S6-1 (KACC93225P) with a food-borne fermentation strain.
상기 인지기능개선 약재군은,
원지, 복령, 참당귀, 은행잎, 오미자, 창포, 지황, 천마, 도라지, 모렐버섯 및 황기 중 하나 이상인 것을 특징으로 하는 인지기능개선용 조성물.
8. The method of claim 7,
The cognitive function improving medicament group includes:
Wherein the composition is at least one selected from the group consisting of Chinese cabbage, Chinese cabbage, true oriental ginkgo, ginkgo leaf, omija, iris, rhubarb, rhinoceros, bellflower, morel mushroom and hwanggi.
상기 인지기능개선용 조성물은,
배양 후 과실액 및 벌꿀 중 하나 이상을 더 포함하는 것을 특징으로 하는 인지기능개선용 조성물.
8. The method of claim 7,
The composition for improving the cognitive function,
Wherein the composition further comprises at least one of a fruit solution and honey after culturing.
상기 인지기능개선용 조성물은,
배양 후 비타민C 및 활성비타민 B군을 더 포함하는 것을 특징으로 하는 인지기능개선용 조성물.
8. The method of claim 7,
The composition for improving the cognitive function,
Wherein the composition further comprises a vitamin C and an active vitamin B group after culturing.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170172982A KR20190071990A (en) | 2017-12-15 | 2017-12-15 | Fermented ginseng and composition for improving cognitive function using a combination fermentation strain |
KR1020200067851A KR102394399B1 (en) | 2017-12-15 | 2020-06-04 | Composition for improving cognitive function |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170172982A KR20190071990A (en) | 2017-12-15 | 2017-12-15 | Fermented ginseng and composition for improving cognitive function using a combination fermentation strain |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020200067851A Division KR102394399B1 (en) | 2017-12-15 | 2020-06-04 | Composition for improving cognitive function |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20190071990A true KR20190071990A (en) | 2019-06-25 |
Family
ID=67065668
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020170172982A KR20190071990A (en) | 2017-12-15 | 2017-12-15 | Fermented ginseng and composition for improving cognitive function using a combination fermentation strain |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20190071990A (en) |
-
2017
- 2017-12-15 KR KR1020170172982A patent/KR20190071990A/en not_active Application Discontinuation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20100081639A1 (en) | Pharmaceutical composition comprising fermented ginseng | |
US11376292B2 (en) | Microbial fermentation composition subjected to enzymolysis, microbial fermentation and microbial transformation and use thereof | |
KR100716123B1 (en) | Food composition comprising fermented dioscorea batatas decne. and the rhizoma thereof with lactic acid for preventing and improving constipation and obesity | |
US20030190377A1 (en) | Novel use of the extract of processed Panax genus plant and saponin compound isolated therefrom | |
KR101651082B1 (en) | A Composition Comprising the Fermentate of Puerariae Radix extract for protecting liver damage | |
KR102394399B1 (en) | Composition for improving cognitive function | |
KR100555652B1 (en) | Extract of processed Panax Species plant, process for preparing the same, and composition containing the same for preventing and treating cancer and allergy- mediated disease | |
KR101951402B1 (en) | Fermentative product of Sagunjatang having brain neuron cell-protective activity and uses thereof | |
KR100848686B1 (en) | A FERMENTED GINSENG COMPOSITION STRENGTHENED SIMULTANEOUSLY WITH γ-AMINOBUTYRIC ACID AND BIOCONVERSION SAPONIN BY LACTIC ACID BACTERIA | |
KR102168192B1 (en) | Healthful mixed tea development using fermented herbs, fruits and shiitake | |
KR100874778B1 (en) | Composition for the prevention and treatment of menopausal diseases comprising fermented Cheonggukjang extract | |
KR102167812B1 (en) | Fermented product of sorghum-adzuki bean mixture for intestinal health and improvement effect of bowel | |
KR20200078171A (en) | The manufacturing method of fermented red ginseng extracts enhanced with ginsenoside compound K, Rd and Rd3 using β-glucosidase and lactic acid bacteria | |
KR20030080296A (en) | Composition containing saponin fraction and derivatives isolated from ginseng radix for preventing and treating allergy-mediated disease | |
KR100919134B1 (en) | Extract of antiobestic ginseng with anti-obesity effect comprising high concentration of less polar ginsenoid and method of preparing the same | |
KR20190071990A (en) | Fermented ginseng and composition for improving cognitive function using a combination fermentation strain | |
KR101470347B1 (en) | A Composition Comprising the Fermentate of Scutellariae Radix extract for protecting liver damage | |
KR101482044B1 (en) | Food composition comprising fermented product of Pleuropterus multiflorus and ginger for alleviating or preventing degenerative brain disorder and method of producing the same | |
KR20130005869A (en) | Red ginseng liquid using two step fermentation of lactic acid bacteria | |
KR100556683B1 (en) | Composition containing an extract of processed Panax Species plant or saponin derivatives therefrom for preventing and treating a gastrointestinal disease | |
KR100533505B1 (en) | Health supplement food containing saponin derivatives isolated from ginseng radix for preventing and treating allergy-mediated disease | |
CN105875903A (en) | Tea product using hawthorn fruits as main raw materials and preparation method thereof | |
KR20090120731A (en) | Compositions for preventing or treating obesity or hypercholestemia | |
KR100551564B1 (en) | Composition containing saponin derivatives isolated from ginseng radix for preventing and treating allergy-mediated disease | |
KR101434444B1 (en) | Preparation Method for an extract enriched with ginsenoside Rg3 from Ginseng Radix |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
X091 | Application refused [patent] | ||
AMND | Amendment | ||
X601 | Decision of rejection after re-examination | ||
WITB | Written withdrawal of application |